Hiram,
I don't think the drug companies are going to go out of
business because people switch to using plant extracts.
Viagra and MUSE both retail for about $10 per dose, and
you said you're *already* getting 10-20 calls per day on Viagra.
Little VVUS sold over $100 M of MUSE hard-ons in their first year.
Well, those Boomer guys calling you are probably not all
impotent; many just want it bigger/harder/longer.
But that's a whole 'nother story, unrelated to LLY.
-----
But I have been doing some thinking about Evista, and,
coming up with some reasons why there is really no
hurry to jump in and buy LLY at prices higher than 60.
The main thing that bothers me is related to your point
about drugs being expensive, and reimbursements cut back.
Well, most every insurance policy I've seen that covers
prescription drugs limits coverage to *treating* illness,
and they typically don't explicitly cover drugs or treatments
for purposes of *preventing* illness. Preventive care is
almost always limited to annual physical exams and associated
blood tests and diagnostic procedures, with some policies
throwing in vasectomies or other procedures that can
minimize future health care costs (e.g., bearing children).
So, Hiram, if Evista is approved now for *preventing*
osteoporosis, how many women are reimbursed by insurers
for this drug?
And, if some users are not reimbursed now, why would this
change if LLY can, in future, add breast cancer prevention and
heart disease prevention to the list of FDA-approved uses?
David |
